Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials

dc.contributor.author	Gómez-Reino Carnota, Juan Jesús
dc.date.accessioned	2017-06-07T06:57:15Z
dc.date.available	2017-06-07T06:57:15Z
dc.date.issued	2014
dc.identifier.issn	2326-5191
dc.identifier.uri	http://hdl.handle.net/20.500.11940/958
dc.language.iso	eng
dc.title	Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: Results from 3 phase 3, randomized, controlled trials
dc.type	Publicación de congreso
dc.authorsophos	Kavanaugh, A.
dc.authorsophos	Cutolo, M.
dc.authorsophos	Mease, P.
dc.authorsophos	Gladman, D. D.
dc.authorsophos	Adebajo, A. O.
dc.authorsophos	Gomez-Reino, J.
dc.authorsophos	Wollenhaupt, J.
dc.authorsophos	Schett, G. A.
dc.authorsophos	Lespessailles, E.
dc.authorsophos	Hu, C. C.
dc.authorsophos	Stevens, R. M.
dc.authorsophos	Edwards, C.
dc.authorsophos	Birbara, C. A.
dc.identifier.doi	http://dx.doi.org/10.1002/art.38914
dc.identifier.sophos	16689
dc.issue.number	Supl
dc.journal.title	Arthritis and Rheumatology
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago - Complexo Hospitalario Universitario de Santiago::Reumatoloxía
dc.page.initial	S239
dc.page.final	S240
dc.rights.accessRights	openAccess
dc.typesophos	Comunicaciones a congresos
dc.volume.number	66

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.